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Protein ruthenation and DNA alkylation:
chlorambucil-functionalized RAPTA
complexes and their anticancer activity
Alexey A. Nazarov,*a,b Samuel M. Meier,c Olivier Zava,a Yulia N. Nosova,b
Elena R. Milaeva,b Christian G. Hartinger*d and Paul J. Dyson*a
Chemotherapeutics for the treatment of tumorigenic conditions that feature novel modes of action are
highly sought after to overcome the limitations of current chemotherapies. Herein, we report the conju-
gation of the alkylating agent chlorambucil to the RAPTA scaﬀold, a well-established pharmacophore.
While chlorambucil is known to alkylate DNA, the RAPTA complexes are known to coordinate to amino
acid side chains of proteins. Therefore, such a molecule combines DNA and protein targeting properties
in a single molecule. Several chlorambucil-tethered RAPTA derivatives were prepared and tested for their
cytotoxicity, stability in water and reactivity to protein and DNA substrates. The anticancer activity of the
complexes is widely driven by the cytotoxicity of the chlorambucil moiety. However, especially in the cis-
platin-resistant A2780R cells, the chlorambucil-functionalized RAPTA derivatives are in general more
cytotoxic than chlorambucil and also a mixture of chlorambucil and the parent organoruthenium RAPTA
compound. In a proof-of-principle experiment, the cross-linking of DNA and protein fragments by a
chlorambucil–RAPTA derivative was observed.
Introduction
Alkylating agents have dominated cancer chemotherapy for
many years, and among many examples of alkylating agents
that have been approved for cancer treatment, the nitrogen
mustard, chlorambucil (Chart 1), is one of the classic anti-
cancer drugs.1–3 Chlorambucil is administered orally4 and has
been mainly used in the treatment of chronic lymphocytic leu-
kemia, but may also be used in the therapy of tumors, such as
certain types of non-Hodgkin lymphoma, trophoblastic neo-
plasms, and ovarian carcinoma. This compound class exhibits
its mode of action through the alkylation of the N7 atoms of
guanine or adenine as well as N3 of adenine in double helical
DNA, which consequently inhibits cell proliferation.5,6
Platinum complexes are often also considered as alkylating
agents as they form coordination bonds to DNA nucleo-
bases.2,7 The potency of platinum complexes in chemotherapy
is unprecedented and they are used to treat many types of
tumors.8–11 However, their disadvantages, in particular, resist-
ance development and side eﬀects, have driven the develop-
ment of metal complexes comprising metal centers other than
platinum.12–14 Ruthenium compounds take a prominent posi-
tion in this development process, as two compounds have
entered clinical trials.15–17 Organometallic RAPTA complexes
are among the most promising ruthenium-based compounds
in preclinical development and although they are essentially
non-cytotoxic in cancer cell lines, they have demonstrated anti-
cancer activity in vivo.17–20 The RAPTA framework (Chart 1)
consists of a ruthenium center, an η6-coordinated arene, typi-
cally p-cymene (RAPTA-C) or toluene (RAPTA-T), the 1,3,5-
triaza-7-phosphaadamantane (PTA) ligand and two chlorido
leaving groups.19,21 The RAPTA scaﬀold can be equipped with
Chart 1 The structures of chlorambucil (left) and the RAPTA scaﬀold
(right).
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functionalities that provide specific properties. For example,
derivatization of the arene ligand with ethacrynic acid resulted
in eﬃcient glutathione-S-transferase inhibitors.22 The mode of
action appears to involve the enzymatic cleavage of the enzyme-
inhibiting moiety from the metal fragment allowing the metal
moiety to target other biomolecules. This represents an
example of a multi-targeted anticancer agent with components
of the same molecule interacting with diﬀerent targets.23 Such
drugs are designed to act against several individual molecular
targets rather than a single enzyme or DNA as the target for
platinum anticancer drugs.24 This approach oﬀers a number
of advantages such as tuneable pharmacological properties
and anticancer activity, and altered metabolism and resistance
development.23,25 An alternative approach for developing
ruthenium-arene multitargeted compounds is through the
coordination of a bioactive ligand to the metal center as
shown for RuII(cym) (cym = η6-p-cymene) complexes of
3-hydroxyflavones,26–28 lapachol,29 paullone,30 and lonidamine31
derivatives and other examples.32 Such an “intramolecular”
combination therapy may also help to overcome disadvantages
and limitations of antineoplastic alkylating agents.
Therefore, we have designed a new compound class that
features the RAPTA framework conjugated with chlorambucil.
Such compounds should be able to alkylate DNA and at the
same time coordinate to proteins through the ruthenium
center while maintaining the structure of the RAPTA pharma-
cophore. This approach is supported by the observation that
RAPTA binds preferentially to proteins through coordination,
as shown in crystallographic experiments using the nucleo-
some core particle (NCP) in which the RAPTA scaﬀold was
found predominantly at the histone proteins.33,34 The syn-
thesis of alkylating RAPTA derivatives was complemented by
studies on the cytotoxic activity in human cancer cell lines and
mass spectrometric investigations with 9-ethylguanine (EtG)
and L-histidine (His), L-methionine (Met) and ubiquitin (Ub) as
DNA and protein models, respectively.
Experimental
Materials
Solvents were purified and degassed prior to use.35 All com-
pounds were obtained from Sigma-Aldrich except for L-histi-
dine which was obtained from Merck; formic acid was from
Fluka; 9-ethylguanine and tetramethylammonium acetate were
from TCI Europe. Methanol (HPLC grade, Fisher) and Milli-
pore water (18.2 MΩ, Advantage A10, 185 UV ultrapure water,
Millipore) were used for ESI-MS studies.
Instrumentation
1H and 31P{1H} NMR spectra were recorded on a Bruker Avance
II 400 spectrometer at room temperature and were referenced
to the 1H signal of the NMR solvent or to H3PO4 as an external
reference for 31P{1H} NMR spectroscopy. ESI mass spectra of
the compounds were obtained in MeOH on a ThermoFinnigan
LCQ Deca XP Plus quadrupole ion-trap instrument operated in
the positive ion mode over m/z 150–1000. The ionization
energy was set at 3.5 kV (capillary voltage) and the capillary
temperature at 150 °C. Melting points were determined with a
Stuart Scientific SMP3 apparatus and are uncorrected. The
flash chromatography system Varian 971-FP was used for puri-
fication. Elemental analyses were carried out by the micro-
analytical laboratory at the EPFL.
Cell lines and culture conditions
Human A2780 and A2780cisR ovarian carcinoma cell lines
were obtained from the European Centre of Cell Cultures
(ECACC, Porton Down, Salisbury, UK). Human MCF-7 breast
carcinoma cells were obtained from the American Type
Culture Collection (ATCC). These cells were routinely grown in
Dulbecco’s modified Eagle medium containing 4.5 g L−1
glucose and glutamax, and were supplemented with 10% heat-
inactivated fetal bovine serum and antibiotics. Cultures were
maintained at 37 °C under a humidified atmosphere contain-
ing 6% CO2. All cell culture reagents were purchased from
Gibco-BRL, Basel, Switzerland. For cell viability experiments
tests, cells were grown on 96-well plates (Costar, Integra Bio-
sciences, Cambridge, MA, USA) as monolayers for 24 h in com-
plete medium with 10% FCS to reach sub-confluence. Then
fresh complete medium with 5% FCS was added together with
the drugs, and the culture was continued for another 72 h. The
compounds were pre-dissolved at 20 mM in DMSO and then
added to the cell culture medium at the required concen-
tration with a maximum DMSO content of 0.5%, v/v, to be
incubated for 72 h. At these concentrations, DMSO has no
eﬀect on cell viability. Cell viability was determined using the
MTT assay, which quantifies the mitochondrial activity in
metabolically active cells, essentially as reported previously.36
Briefly, following drug exposure, MTT (Sigma, final concen-
tration 0.2 mg ml−1) was added to the cell culture medium for
the final 2 h, and then the culture medium was aspirated and
the violet formazan precipitate dissolved in 0.1 M HCl in 2-pro-
panol. The optical density, which is directly proportional to
the number of surviving cells, was quantified at 540 nm using
a multiwell plate reader (iEMS Reader MF, Labsystems, USA)
and the percentage of surviving cells was calculated from the
absorbance of untreated cells.
Synthesis
4-(p-(Bis(2-chloroethyl)amino)phenyl)-N-(cyclohexa-1,4-dien-
1-ylmethyl)butanamide (2). A solution of 4-(p-(bis(2-chloro-
ethyl)amino)phenyl)butanoyl chloride37 (5.0 g, 15.5 mmol) in
CH2Cl2 (60 mL) was added dropwise to a stirred solution of
1,4-cyclohexadiene-1-methanamine38 (1.85 g, 16.95 mmol) and
triethylamine (3.5 mL, 25.2 mmol) in CH2Cl2 (120 mL). The
reaction mixture was stirred for 12 h at room temperature. The
solvent was evaporated, and the semicrystalline solid was sus-
pended in toluene (25 mL). Triethylamine hydrochloride was
removed by filtration and washed with toluene (3 × 5 mL). The
toluene was removed under reduced pressure and the crude
product was purified by column chromatography using
CH2Cl2–MeOH (98 : 2). Yield: 4.8 g (78.3%), mp: 98–99 °C,
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elem. anal. calcd (%) for C21H28Cl2N2O: C 63.80, H 7.14,
N 7.09; found: C 64.08, H 7.21, N 7.23. 1H NMR (400.13 MHz,
CDCl3): δ = 7.09 (d, J = 8.3 Hz, 2H; Har), 6.64 (d, J = 8.3 Hz, 2H,
Har), 5.72 (s, 2H; CH), 5.60 (s, 1H; CH), 5.42 (brs, 1H; NH), 3.81
(d, J = 5.4 Hz, 2H; CH2NHC(O)), 3.72 (m, 4H; NCH2CH2Cl), 3.64
(m, 4H; NCH2CH2Cl), 2.71 (m, 2H; CH2C6H4), 2.65–2.57 (m, 4H,
CH2diene), 2.12 (tr, 2H, CH2CH2C(O)), 1.96 (m, 2H, CH2CH2C(O))
ppm. MS (ESI+): m/z 395 [M + H]+.
4-(p-(Bis(2-chloroethyl)amino)phenyl)-N-(cyclohexa-1,4-dien-
1-ylethyl)butanamide (3). Similarly to 2, compound 3 was
prepared from 4-(p-(bis(2-chloroethyl)amino)phenyl)butanoyl
chloride37 (5.0 g, 15.5 mmol), 1,4-cyclohexadiene-1-ethan-
amine38 (2.03 g, 16.5 mmol) and triethylamine (3.5 mL,
25.1 mmol). Yield: 3.9 g (61.4%), mp: 103–105 °C, elem. anal.
calcd (%) for C22H30Cl2N2O: C 64.54, H 7.39, N 6.84; found:
C 64.72, H 7.71, N 6.85. 1H NMR (400.13 MHz, CDCl3): δ = 7.09
(d, J = 8.6 Hz, 2H; Har), 6.66 (d, J = 8.6 Hz, 2H, Har), 5.73 (s, 2H;
CH), 5.51 (s, 1H; CH), 5.42 (brs, 1H; NH), 3.72 (m, 4H;
NCH2CH2Cl), 3.64 (m, 4H; NCH2CH2Cl), 3.39 (m, 2H;
CH2CH2NH), 2.71 (m, 2H; CH2C6H4), 2.64–2.55 (m, 4H,
CH2diene), 2.21–2.15 (m, 4H, CH2CH2NH, CH2CH2C(O)), 1.94
(m, 2H, CH2CH2C(O)) ppm. MS (ESI
+): m/z 409 [M + H]+.
Bis[dichlorido(η6-N-benzyl-4-(p-(bis(2-chloroethyl)amino)-
phenyl)butanamide)ruthenium(II)] (4). A solution of 4-(p-(bis-
(2-chloroethyl)amino)phenyl)-N-(cyclohexa-1,4-dien-1-ylmethyl)-
butanamide (3.0 g, 7.6 mmol) in degassed ethanol (150 mL)
was added to ruthenium(III) chloride hydrate (0.52 g,
2.0 mmol). The reaction mixture was refluxed at 90 °C for 10 h
under nitrogen and a black solid was filtered oﬀ. An orange
precipitate was obtained from the filtrate after keeping it for
12 h at −4 °C. The product was filtered, washed with cold
ethanol (1 × 5 mL) and diethyl ether (2 × 5 mL) and dried
in vacuo. Yield: 0.6 g (53.0%), mp: 188–190 °C (decomp.), elem.
anal. calcd (%) for C42H52N4O2Ru2Cl8: C 44.62, H 4.64, N 4.96;
found: C 45.01, H 4.21, N 5.11. 1H NMR (400.13 MHz, CDCl3):
δ = 7.61 (tr, J = 5.9 Hz, 2H; NH), 7.16 (d, J = 8.3 Hz, 4H, Har),
6.67 (d, J = 8.3 Hz, 4H, Har), 5.66 (s, 6H; Har), 5.45 (s, 4H; Har),
4.45 (d, J = 6.4 Hz, 4H; CH2NH), 3.72 (m, 8H; NCH2CH2Cl),
3.66 (m, 8H; NCH2CH2Cl), 2.71 (tr, J = 7.3 Hz, 4H; CH2C6H4),
2.52 (tr, J = 7.3 Hz, 4H, CH2CH2C(O)), 2.04 (tr, J = 7.3 Hz, 4H,
CH2CH2C(O)) ppm. MS (ESI
+): m/z 1093 [M − Cl]+.
Bis[dichlorido(η6-(4-(p-(bis(2-chloroethyl)amino)phenyl)-N-
phenethylbutanamide))ruthenium(II)] (5). Similar to 4, com-
pound 5 was synthesised from 4-(p-(bis(2-chloroethyl)amino)-
phenyl)-N-(cyclohexa-1,4-dien-1-ylethyl)butanamide (3.1 g,
7.6 mmol) and ruthenium(III) chloride hydrate (0.52 g,
2.0 mmol). Yield: 0.83 g (71.6%), mp: 190–192 °C (decomp.),
elem. anal. calcd (%) for C44H56N4O2Ru2Cl8: C 45.61, H 4.87,
N 4.84; found: C 45.63, H 5.12, N 5.01. 1H NMR (400.13 MHz,
CDCl3): δ = 7.12 (d, J = 8.5 Hz, 4H; Har), 6.96 (d, J = 7.3 Hz, 4H,
Har), 6.58 (brs, 2H, NH), 5.73 (tr, J = 5.6 Hz, 2H; Har), 5.60
(tr, J = 5.6 Hz, 4H; Har), 5.43 (d, J = 5.9 Hz, 4H; Har), 3.75–3.64
(m, 20H, CH2CH2NH, NCH2CH2Cl), 2.80 (tr, J = 6.2 Hz, 4H;
CH2CH2NH), 2.59 (tr, J = 7.3 Hz, 4H; CH2C6H4), 2.23 (tr, J =
7.3 Hz, 4H, CH2CH2C(O)), 1.94 (m, 4H, CH2CH2C(O)) ppm. MS
(ESI+): m/z 1121 [M − Cl]+.
[Dichlorido(η6-N-benzyl-4-(p-(bis(2-chloroethyl)amino)phenyl)-
butanamide)(1,3,5-triaza-7-phosphaadamantane)ruthenium(II)]
(6). A solution of PTA (32 mg, 0.2 mmol) in methanol (5 mL)
was added to a solution of 4 (113 mg, 0.1 mmol) in dichloro-
methane (20 mL) under nitrogen. The reaction mixture was
stirred for 12 h at room temperature. The reaction mixture was
concentrated in a vacuum and diethyl ether was added. The
precipitate was separated by filtration, washed with diethyl ether
(3 × 5 mL), and dried in vacuo. Yield: 82 mg (56.8%), mp:
171–172 °C (decomp.), elem. anal. calcd (%) for C27H38N5ORuCl4P:
C 44.89, H 5.30, N 9.69; found: C 44.87, H 5.12, N 10.03.
1H NMR (400.13 MHz, CDCl3): δ = 7.10 (d, J = 8.8 Hz, 2H,
Har),7.05 (tr, J = 5.8 Hz, 1H; NH), 6.63 (d, J = 8.8 Hz, 2H, Har),
5.60 (m, 2H; Har), 5.55 (m, 2H; Har), 5.14 (m, 1H; Har), 4.55
(s, 6H; CH2), 4.45 (d, J = 5.8 Hz, 2H; CH2NH), 4.34 (s, 6H; CH2),
3.71 (m, 4H; NCH2CH2Cl), 3.64 (m, 4H; NCH2CH2Cl), 2.59 (tr,
J = 7.3 Hz, 2H; CH2C6H4), 2.31 (tr, J = 7.3 Hz, 2H, CH2CH2C(O)),
1.97 (q, J = 7.3 Hz, 2H, CH2CH2C(O)) ppm.
31P{1H} NMR
(161.98 MHz, CDCl3): δ = −33.2 ppm.MS (ESI+): m/z 686 [M − Cl]+.
[Dichlorido(η6-N-benzyl-4-(p-(bis(2-chloroethyl)amino)phenyl)-
butanamide)(3,7-diacetyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]-
nonane)ruthenium(II)] (7). Similar to 6, compound 7 was pre-
pared by reacting 4 (100 mg, 0.09 mmol) with 3,7-diacetyl-
1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane (40 mg, 0.18 mmol).
Yield: 100 mg (70.0%), mp: 133–135 °C (decomp.), elem. anal.
calcd (%) for C30H42N5O3RuCl4P: C 45.35, H 5.33, N 8.81;
found: C 45.65, H 5.48, N 8.82.1H NMR (400.13 MHz, CDCl3):
δ = 8.34 (tr, J = 5.6 Hz, 1H; NH), 7.01 (d, J = 8.5 Hz, 2H, Har),
6.66 (d, J = 8.7 Hz, 2H, Har), 5.99 (m, 2H; Har), 5.77 (m, 2H;
Har), 5.56 (d, J = 13.4 Hz, 2H, NCH2N), 5.49 (tr, J = 5.3 Hz, 1H;
Har), 5.28 (dd, J = 15.2, 7.6 Hz, 1H, NCH2P), 4.98 (d, J =
13.7 Hz, 1H, NCH2N), 4.66 (d, J = 14.0 Hz, 1H, NCH2N), 4.49
(dd, J = 15.5, 8.8 Hz, 1H, NCH2P), 4.21 (m, 2H, NCH2P), 4.13
(d, J = 13.5 Hz, 2H, NCH2N), 4.09–3.90 (m, 2H, NCH2N),
3.75–3.66 (m, 8H; NCH2CH2Cl), 2.49 (tr, J = 7.3 Hz, 2H;
CH2C6H4), 2.15 (tr, J = 7.3 Hz, 2H, CH2CH2C(O)), 1.97 (s, 3H,
CH3), 1.90 (s, 3H, CH3), 1.74 (q, J = 7.3 Hz, 2H, CH2CH2C(O))
ppm. 31P{1H} NMR (161.98 MHz, CDCl3): δ = −11.7 ppm. MS
(ESI+): m/z 758 [M − Cl]+.
[Dichlorido(η6-N-benzyl-4-(p-(bis(2-chloroethyl)amino)phenyl)-
butanamide)(3,5,6-bicyclophosphite-1,2-O-isopropylidene-α-D-
glucofuranoside)ruthenium(II)] (8). Similar to 6, complex 8
was prepared from 4 (100 mg, 0.09 mmol) and 3,5,6-bicyclo-
phosphite-1,2-O-isopropylidene-α-D-glucofuranoside (44 mg,
0.18 mmol). Yield: 111 mg (77.6%), mp: 112–113 °C
(decomp.), elem. anal. calcd (%) for C30H39N2O7RuCl4P:
C 44.29, H 4.83, N 3.44; found: C 43.97, H 4.86, N 3.54.
1H NMR (400.13 MHz, CDCl3): δ = 7.12 (d, J = 8.3 Hz, 2H, Har),
6.97 (brs, 1H; NH), 6.66 (d, J = 8.8 Hz, 2H, Har), 6.18 (d, J =
3.4 Hz, 1H, H-1), 5.94 (tr, J = 5.9 Hz,1H; Har), 5.86 (tr, J =
5.4 Hz, 1H; Har), 5.80 (m, 2H; Har), 5.48 (tr, J = 5.4 Hz, 1H;
Har), 5.07 (m, 1H; H-5), 4.80 (s, 1H; H-3), 4.73 (d, J = 3.4 Hz,
1H; H-2), 4.60–4.39 (m, 3H; H-6, CH2NH), 4.31 (m, 2H;
H-4, H-6′), 3.72 (m, 4H; NCH2CH2Cl), 3.67 (m, 4H;
NCH2CH2Cl), 2.62 (tr, J = 7.3 Hz, 2H; CH2C6H4), 2.34 (tr, J = 7.3
Hz, 2H, CH2CH2C(O)), 1.99 (q, J = 7.8 Hz, 2H, CH2CH2C(O)),
Paper Dalton Transactions
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1.53 (s, 3H, CH3), 1.36 (s, 3H, CH3) ppm.
31P{1H}
NMR (161.98 MHz, CDCl3): δ = 133.2 ppm. MS (ESI
+): m/z 835
[M + Na]+.
[Dichlorido(η6-(4-(p-(bis(2-chloroethyl)amino)phenyl)-N-
phenethylbutanamide)(1,3,5-triaza-7-phosphaadamantane)-
ruthenium(II)] (9). Similar to 6, compound 9 was synthesized
from PTA (32 mg, 0.2 mmol) and 5 (116 mg, 0.1 mmol). Yield:
107 mg (72.6%), mp: 116–118 °C (decomp.), elem. anal. calcd
(%) for C28H40N5ORuCl4P: C 45.66, H 5.47, N 9.51; found:
C 45.54, H 5.35, N 9.67. 1H NMR (400.13 MHz, d7-DMF): δ =
7.35 (brs, 1H, NH), 7.09 (d, J = 8.5 Hz, 2H; Har), 6.73 (d, J =
8.8 Hz, 2H, Har), 5.62 (m, 2H; Har), 5.58 (m, 2H; Har), 5.54
(m, 2H; Har), 4.53 (s, 6H; CH2), 4.35 (s, 6H; CH2), 3.76 (m, 8H,
NCH2CH2Cl), 3.60 (m, 2H, CH2CH2NH), 2.71 (tr, J = 6.4 Hz,
2H; CH2CH2NH), 2.50 (tr, J = 7.3 Hz, 2H; CH2C6H4), 2.19 (tr,
J = 7.6 Hz, 2H, CH2CH2C(O)), 1.85 (m, 2H, CH2CH2C(O)) ppm.
31P{1H} NMR (161.98 MHz, d7-DMF): δ = −33.0 ppm. MS (ESI+):
m/z 700 [M − Cl]+.
Protein and DNA binding studies
Complex 6 (25 µM) was incubated at 37 °C in 1% DMSO–water
or in 1 mM tetramethylammonium acetate with 9-ethylguanine
(EtG) or ubiquitin (Ub) at metal-to-biomolecule ratios of 1 : 2
and 1 : 1, respectively. Complex 6 was also incubated with both
EtG and Ub at molar ratios of 1 : 2 : 1 and 2 : 8 : 1 giving a final
protein concentration of 25 µM. Aqueous solutions of 6 were
analyzed for comparison purposes under the same conditions
as the biomolecule-containing reaction mixtures. In a further
set of experiments, histidine (His) and methionine (Met) were
separately preincubated with 6 for 1 h in buﬀered solution
prior to the addition of EtG giving a final molar ratio of
2 : 1 : 4. Prior to analysis, the incubation mixtures were
diluted with water 1 : 5 in the case of the low-molecular weight
biomolecules and 1 : 1 for ubiquitin-containing samples,
corresponding to 5 µM complex and 12.5 µM protein, respect-
ively. Protein samples were analyzed under non-denaturing
conditions.
To characterize the adducts formed between 6 and the bio-
molecules, full mass spectra were recorded in the m/z range of
70–2500 on a Bruker Maxis UHR qTOF (capillary −4500 V, dry
gas 6.0 l min−1, nebulizer 0.6 bar, dry temperature 180 °C),
and collision-induced MSn experiments were conducted on a
Bruker Amazon SL ion trap under similar source conditions.
Data analysis was done with the Bruker data analysis software
ESI Compass 1.3 and DataAnalysis 4.0 (build 234). Protein
mass spectra were deconvoluted using the maximum entropy
deconvolution algorithm with automatic data point spacing
and 30 000 resolving power.
Results and discussion
We decided to combine the RAPTA pharmacophore, which has
a ruthenium(II) center able to bind to histone proteins,33,34
with the alkylating moiety found in the anticancer drug chlor-
ambucil 1, which is known to act as a DNA alkylating agent.5,6
The chlorambucil group was conjugated to the RAPTA scaﬀold
by derivatization of the arene ring with chlorambucil via an
amide bond to the piano-stool Ru complex. The PTA co-ligand
was also varied with 3,7-diacetyl-1,3,7-triaza-5-phosphabicyclo-
[3.3.1]nonane (DAPTA) and glucose phosphite ligands. The
synthetic route used is similar to the one reported earlier for
the preparation of RAPTA compounds carrying ethacrynic
acid,22 a naphthalimide intercalator39 or a fluorescent tag.40
Chlorambucil was converted into the acid chloride by oxalyl
chloride–DMF and reacted with 1,4-cyclohexadiene-1-methyl-
amine or 1,4-cyclohexadiene-1-ethylamine to yield 4-(p-(bis-
(2-chloroethyl)amino)phenyl)-N-(cyclohexa-1,4-dien-1-ylmethyl)-
butanamide and 4-(p-(bis(2-chloroethyl)amino)phenyl)-N-
(cyclohexa-1,4-dien-1-ylethyl)butanamide, respectively. These
dienes were reacted with RuCl3 in ethanol under reflux to
aﬀord the respective RuII(arene) dimers as orange solids
(Scheme 1). Finally, the dimers were treated with PTA, DAPTA
or 3,5,6-bicyclophosphite-1,2-O-isopropylidene-α-D-glucofura-
noside to yield complexes 6–9. The compounds were character-
ized by NMR spectroscopy, mass spectrometry and elemental
analysis. 31P{1H} NMR spectroscopy was used to monitor the
formation of complexes 6–9. In these spectra a shift from ca.
−100 to −33 ppm, from −78 to −17 ppm and from 119 to
133 ppm was observed for the 31P nuclei in the PTA, DAPTA
and phosphite ligands, respectively, upon coordination to the
ruthenium center. In addition, characteristic shifts in the 1H
NMR spectra were observed, as reported for similar types of
complexes,40,41 confirming the proposed structures of the com-
plexes. Compounds 6–9 are stable in CDCl3 and DMF solution
and no decomposition or release of the arene moiety was
observed.
The cytotoxicity of the chlorambucil-functionalized RAPTA-
type complexes (6–9) was evaluated on human ovarian cancer
(A2780) cells, their cisplatin-resistant variant (A2780R) and a
human breast cancer (MCF7) cell line. In addition, studies
mixing chlorambucil and RAPTA-T at a molar ratio of 1 : 1, as
the closest structural analogue to 6–9, were conducted and
compared to RAPTA-T as the parent compound (Table 1). In
general, most of the compounds were more active in the
ovarian cancer cell lines than in MCF7. While RAPTA-T is not
cytotoxic under the applied conditions in the three cell lines,
the chlorambucil-functionalized complexes are active in the
low µM range. Both chlorambucil 1 and a 1 : 1 mixture of
RAPTA-T with 1 show similar cytotoxicity profiles to complexes
6–9 suggesting that the alkylating agent determines the cyto-
toxicity of the complexes. Notably, 1 and a 1 : 1 mixture of
RAPTA-T with 1 show virtually identical IC50 values in the cell
lines. This is not surprising given the fact that RAPTA com-
pounds are not cytotoxic. Furthermore, the nature of the phos-
phorus donor co-ligand is of low importance with the
exception of 7 in MCF7 cells. The cytotoxicity decreases in all
cell lines for 6 over 9. This may be related to 9 having a longer
linker between the chlorambucil moiety and the arene moiety
and being therefore more flexible than 6 and 9. In the
A2780 and MCF7 cell lines there does not appear to be any
advantage in conjugating 1 with a RAPTA fragment, whereas in
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the cisplatin-resistant cell line A2780R, complexes 6–8 are
considerably more potent than 1 and the mixture of 1 with
RAPTA-T. This observation suggests that conjugation of 1 to
Ru(arene) compounds, irrespective of the phosphorus donor
co-ligand, provides a means to overcome cisplatin-induced
resistance mechanisms in cancer cells.
Compound 6 was selected for stability studies and sub-
sequent experiments to demonstrate the cross-linking ability
of biomolecules as it possesses the optimum cytotoxicity pro-
perties of the compound series and also reasonably soluble in
aqueous solution. Furthermore, the experiments are not inter-
fered by the instability of the DAPTA ligand in 7 or the compli-
cated hydrolysis pathways of the glucose-derived phosphite
in 8.41
Initially, the hydrolysis behavior of 6 was studied after dis-
solving the compound in 1% DMSO–water. Immediate analysis
showed the presence of a single peak in the ESI mass spectrum
at m/z 688.0891, which was assigned to the ion [M − Cl]+ (see
Table 2 for experimental and simulated mass signals;
Scheme 2). The same mixture was analyzed over a period of 2
days revealing that 6 starts to hydrolyze, to some extent, after
incubation for 1.5 h as indicated by the appearance of hydrox-
ide-containing mass signals, corresponding to [6 − 2Cl + OH]+
(Fig. 1A). Simultaneously, 6 starts to release the activated aziri-
dinium chlorambucil-arene ligand [L − Cl]+. After 21 h, the
ligand release is quantitative and is accompanied by the for-
mation of Ru(PTA)Cl species, which appear to be stabilized by
DMSO, e.g., [Ru(PTA)(DMSO)nCl]
+ (n = 2, 3). Within the same
time frame, the activated chlorambucil is converted completely
into the dihydroxyl species L2OH as indicated by the change in
the isotopic pattern and a small mass shift from m/z 357.1711
to 357.2180 (Fig. 1B). There was no further change in the mass
spectrum from 21 to 72 h. In order to characterize this species
further, collision-induced tandem mass spectrometric experi-
ments were conducted using L2OH at m/z 357.1 as the precur-
sor ion. A monohydroxyl LOH ion was detected at m/z 340.1,
together with an amide-cleaved product ion at m/z 250.1 and
neutral loss products at m/z 232.1 (–H2O) and 214.0 (–2H2O),
all underlining the identity of the parent mass signal.
Hydrolysis of 6 in tetramethylammonium acetate buﬀer is
similar to that observed in water. Hydrolysis products of intact
6 are observed after 10 min, including an additional acetate
adduct [6 − 2Cl + CH3COO]+ from the buﬀer as the most abun-
Scheme 1 Synthetic route to the chlorambucil-functionalized ruthenium complexes with amphiphilic phosphorus-based co-ligands.
Table 1 Cytotoxicity of 1, 6–9, RAPTA-T and 1 + RAPTA-T (1 : 1) in the
human ovarian cancer cells A2780, their cisplatin-resistant variant
A2780R and MCF7 breast cancer cells
Compound
IC50 (µM)
A2780 A2780R MCF7
1 5.2 ± 1.6 25 ± 4 22 ± 7
RAPTA-T >200 >200 >200
1 + RAPTA-T (1 : 1) 5.2 ± 1.6 25 ± 3 25 ± 9
6 8.3 ± 1.3 10 ± 3 12 ± 4
7 9.4 ± 2.2 7.0 ± 0.8 42 ± 7
8 8.2 ± 2.3 8.7 ± 0.9 14 ± 1
9 12 ± 4 45 ± 17 37 ± 9
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dant peak. Similarly, intact 6 disappeared completely due to
release of the chlorambucil-arene ligand within 20 h, which
was detected in the dihydroxyl form L2OH. One additional
mass signal with a ruthenium isotope pattern was observed at
m/z 474.0238, which was attributed to [Ru(PTA)(DMSO)2 +
CH3COO]
+. The mass shifts are also accompanied by a change
in isotope pattern due to the absence of chloride in the
detected species. It should be noted that the arene ligand in
other RAPTA derivatives is strongly bound to the Ru center.34
Compound 6 was designed with the aim to provide a com-
pound able to alkylate DNA and simultaneously coordinate to
proteins. In order to demonstrate the ability of 6 to cross-link,
its reactivity was investigated with the DNA model nucleobase
EtG and His and Met as protein building blocks. Thus, 6 was
incubated with EtG (1 : 2), His or Met (1 : 2) and with both (6 :
EtG : His/Met = 1 : 4 : 2) and the solutions were analyzed by
ESI-TOF mass spectrometry.
Incubation of 6 with EtG in water resulted immediately
in the detection of several EtG–ruthenium adducts besides
the mass signals caused by hydrolysed 6. Accordingly, mono-
chlorido, mono-hydroxido and EtG coordination adducts were
observed for hydrolysed 6, e.g. [6 − Cl + EtG]+ and [6 − 2Cl
− H + EtG]+. After about 16 h, the arene ligand was cleaved to
some extent and underwent again Cl/OH substitution
(Scheme 2), as indicated by the signals at m/z 357, which
became the most intense signal in the mass spectrum.
However, there were still coordination adducts of EtG detect-
able, such as [(L2OH)Ru(PTA) + EtG]2+, although at low relative
abundance. Continuing the incubation for another 48 h did
not result in significant changes to the mass spectra. Although
arene release is observed to some extent in parallel with the
experiments in pure water, the addition of EtG seems to stabil-
ize the arene coordination.
In general, the arene ligand steadily dissociates with time
and a species detected at m/z 375.1804 after 1.5 h, which indi-
cates hydrolysis of the aziridinium forming [L − Cl + OH]+.
Finally, after three days of incubation with EtG, a chlorambu-
cil–EtG adduct is observed corresponding to [LOH − Cl + EtG]+
at m/z 518.2880 (Fig. 1C). Therefore, it seems that the DNA-
alkylation reaction with the chlorambucil fragment is much
slower than the hydrolysis and complexation reactions of the
ruthenium ion. Based on this hypothesis it is possible to dis-
tinguish EtG complexation from EtG alkylation.
In tetramethylammonium acetate buﬀer (1 mM), the peak
assigned to [6 − 2Cl − H + EtG]+ was detected after 15 min in
54% relative abundance. In light of the observations made in
water, this peak is assumed to be due to the coordination of
EtG to the ruthenium center rather than an alkylation product.
Unreacted and hydrolyzed 6 were also detected in the forms of
[6 − 2Cl + CH3COO]+, [6 − Cl]+, [6 − 2Cl + OH]+ and [6 − 2Cl]2+.
After 20 h, the most abundant signal in the mass spectrum
besides the acetate adduct [Ru(PTA)(DMSO)2 + CH3COO]
+ cor-
responded to cleavage of the arene. Moreover, the alkylated
EtG species [LOH − Cl + EtG]+ was already detected after this
Table 2 Selected detected ions during the experiments with small molecules in buﬀered and unbuﬀered aqueous solutions, showing their accurate
(macc) and exact masses (mex) recorded on a high resolution ESI-TOF MS instrument. Ac is acetate
Species macc mex Δppm
Compound [(LCl)Ru(PTA)(His)(EtG) + DMSO + H2O − 2H]+ 1044.3333 1044.3138 18.7
[(LCl)Ru(PTA)(Met)(EtG) + DMSO + H2O − 2H]+ 1038.3129 1038.2953 17.0
[(LOH)Ru(PTA)(His) + EtG − 2H]+ 930.3142 930.3235 10.0
[6 − Cl + EtG]+ 867.1720 867.1698 2.5
[6 − 2Cl + His + CH3COO]+ 865.1925 865.2060 15.6
[6 − 2Cl − H + OH + EtG]+ 847.2059 847.2066 0.8
[6 − 2Cl + EtG − H]+ 829.1921 829.1961 4.8
[6 − 2Cl + His − H]+ 805.1725 805.1848 15.3
[6 − 2Cl + Met − H]+ 799.1547 799.1663 14.5
[(LOH)Ru(PTA) + EtG + OH − H]+ 793.2534 793.2645 14.0
[(LOH)Ru(PTA) + EtG − 2H]+ 775.2537 775.2539 0.3
[6 − 2Cl + Ac]+ 712.1332 712.1355 3.2
[6 − Cl]+ 688.0891 688.0900 1.3
[6 − 2Cl + OH]+ 668.1256 668.1258 0.3
[(L2OH)Ru(PTA)Cl]+ 650.1573 650.1799 34.8
[Ru(PTA)(DMSO)2 + EtG − H]+ 593.0883 593.0817 11.1
[Ru(PTA)(DMSO)3Cl]
+ 527.9909 527.9912 0.6
[Ru(PTA)(DMSO)2 + CH3COO]
+ 474.0238 474.0220 3.8
[Ru(PTA)(DMSO)2Cl]
+ 449.9782 449.9772 2.2
[6 − 2Cl + EtG]2+ 415.1013 415.1017 1.0
[(L2OH)Ru(PTA) + EtG]2+ 397.1362 397.1359 0.8
[(LOH)Ru(PTA) + EtG − H]2+ 388.1315 388.1306 2.3
[Ru(PTA)(DMSO) + 2EtG]2+ 347.5747 347.5780 9.5
[6 − 2Cl]2+ 326.5623 326.5608 4.6
[Ru(PTA) + 2EtG]2+ 308.5734 308.5710 7.8
Ligand [LOH − Cl + EtG]+ 518.2880 518.2874 1.2
[LOH − Cl + H]+ 375.1804 375.1834 8.0
[L2OH − H]+ 357.2180 357.2173 2.0
[L − Cl]+ (aziridinium) 357.1711 357.1728 4.8
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time period. Increasing the pH seems to result in an increased
rate of alkylation, in accordance with the mode of action of
chlorambucil.5,6 Additionally, an EtG alkylation product was
detected at m/z 775.2537 corresponding to [(LOH)Ru(PTA) +
EtG − 2H]+.
In an attempt to saturate the hydrolyzed coordination sites
at the ruthenium center in 6 prior to incubation with EtG in
buﬀer, the compound was preincubated with 2 equivalents of
His or Met for 1 h. Analysis of the reaction mixtures revealed
the formation of [6 − 2Cl + AA − H]+ (Scheme 2), where AA =
His or Met, and additionally [6 − 2Cl + His + CH3COO]+. Inter-
estingly, the mass spectra of these reactions recorded 19 h
after the addition of 4 equivalents of EtG were very similar to
each other except for a mass shift of 6 Da (His 155.2 g mol−1;
Met 149.2 g mol−1) indicating that both amino acids co-
ordinated tightly to the complex and stabilized the hydrolyzed
complex against loss of the arene (Fig. 2). Two peaks that were
not shifted are the ones with m/z 755 and 357, corresponding
to the alkylated EtG adduct [(LOH)Ru(PTA) + EtG − 2H]+ and
free L2OH, respectively, which were also found during the
experiments of 6 with EtG alone. Of note are the mass signals
at m/z 1038 and 1044 for Met and His containing reaction mix-
tures, respectively. The isotopic pattern of both mass signals
is indicative of molecules containing one chloride and one
ruthenium. Fragmentation of these mass signals in MSn
experiments on an ion trap instrument by collision-induced
dissociation yielded very similar product spectra again featur-
ing 6 Da diﬀerences suggesting that the amino acids remain
coordinated to the smallest fragments. The MS2 spectra are
very similar to the full mass spectra and, consequently, these
peaks may be tentatively attributed to [(LCl)Ru(PTA)(EtG) + AA
+ DMSO + H2O − H]+, where LCl is a chloride-containing arene
and AA is either His or Met. The DMSO and water adducts
may be caused by clustering, which is underlined by very
broad signals in the full mass spectra. Furthermore, in the
reaction mixture containing His, a signal at m/z 670.05 corres-
Scheme 2 Identiﬁed species from the reaction pathways of 6 with small molecules. The compound was initially dissolved in aqueous 1% DMSO
and samples were diluted with water prior to analysis. Hydrolysis of the metal–chloride bonds is fast with respect to alkylation of the DNA model
9-ethylguanine (EtG). The hydrolysis of chlorambucil can be well followed. The species identiﬁed in 1% DMSO/H2O and due to the ligand release
were also observed in incubations with EtG and His/EtG.
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ponds to [Ru(PTA)(His)(EtG) + DMSO − H]+ and indicates
that in this case, EtG is not alkylated by the chlorambucil
ligand, but is rather coordinated to the metal. Accordingly,
the mass signals were attributed to identical species contain-
ing Met.
Finally, a mass signal corresponding to an alkylated EtG
adduct containing coordinated His [(LOH)Ru(PTA)(His) + EtG −
2H]+ was observed in the TOF mass spectra at m/z 930.3142 in
low abundance. However, this species was not detected in the
MSn fragmentation spectra. Thus, it appears that amino acid
coordination and simultaneous EtG alkylation is possible, but
only to minor extents.
Hydrolysis of the metal–chloride bonds and coordination of
biomolecules take place within several hours whereas alky-
lation requires longer reaction times. Therefore, stabilization
of the metal–arene coordination is crucial for a synergistic
antiproliferative activity. It appears that the presence of small
nucleophilic molecules, e.g. EtG, His or Met, may stabilize the
coordination of the arene to the ruthenium and the formed pro-
ducts were stable over several days. Moreover, the PTA remains
tightly coordinated as well, so that the RAPTA core remains
intact. Increased pH conditions also seem to increase the reac-
tion kinetics for both hydrolysis/coordination and alkylation.
Complex 6 was also incubated with ubiquitin (2 : 1) or with
a mixture of EtG and Ub (2 : 4 : 1) in water and tetramethyl-
ammonium acetate (1 mM). Ubiquitin is a low molecular
weight protein well-suited for MS experiments and ruthenium
arene complexes are known to coordinatively bind to it.42 Incu-
bation of 6 with Ub showed a similar hydrolysis behavior to
that observed in the stability studies and only very minor
adducts were observed even after 69 h of incubation, mainly
corresponding to Ru(PTA)Cl and Ru(PTA)(DMSO) adducts.
Fewer 6–Ub adducts were observed in the presence of 2 equiva-
lents of EtG in the reaction mixture. However, after 69 h, an
adduct between hydrolyzed 6 and EtG is observed at m/z 829
which was also detected during incubation with EtG alone.
Fig. 1 (A) Mass spectra recorded during hydrolysis experiments of 6 in water after 1.5 and 21 h. Compound 6 was dissolved in DMSO and further
diluted with water before analysis. (B) Experimental and simulated isotopic patterns of the diﬀerent released chlorambucil-arene species in
unbuﬀered solution: the aziridinium chlorambucil-arene and aziridinium hydroxyl ligands were detected after 1.5 h, the dihydroxyl ligand after 21 h
and the alkylated 9-ethylguanine (EtG) hydroxyl ligand after 69 h. A higher pH value also increases the kinetics for EtG alkylation.
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The detected Ub adducts are similar to those observed during
the incubation without EtG. Of note is a +10 charged protein
mass signal at m/z 1904.19, which was observed at low abun-
dance after 69 h. This mass signal suggests the presence of a
ruthenium cross-linked Ub dimer, tentatively attributed to [Ub
+ Ru(DMSO) + (LOH)Ru(PTA)(EtG)]2
10+ (Fig. 3), showing that
the compound may cross-link a DNA base with a protein,
albeit in low yield.
The reaction of 6 with Ub in tetramethylammonium acetate
proceeds similarly to water. However the reaction appears to
be more selective. In the presence of EtG, adduct formation is
similar, yielding the Ru(PTA)(DMSO) adduct as the most preva-
lent species and after 44 h a mass signal corresponding to
[LOH − Cl + EtG]+ is clearly observed.
The molar ratio of EtG was increased to 8 equivalents with
respect to 6 during the reaction with Ub in buﬀered water. This
did not influence the extent and the type of adducts. However,
several small molecules formed featuring the characteristic
ruthenium isotope pattern. Among these were several DMSO-
stabilized species with up to two coordinated EtG, which under-
went release of the arene, and accordingly, free L2OH was
detected. Furthermore, [LOH − Cl + EtG]+ was observed after 24 h
and slightly increased with time. Of note is an additional mass
signal, which was found at m/z 793. This species may corre-
spond to [(LOH)Ru(PTA) + EtG + OH − H]+ and appears to further
underline the alkylation of EtG. Themass-to-charge ratio suggests
again that this species would be +3 charged, which is decreased
to +1 by the addition of hydroxide and loss of a proton.
Conclusions
The combination of more than one pharmacophore has been
shown to be a useful strategy for improving the anticancer
activity of compounds with modes of action diﬀerent from
those of established drug compounds. Herein, we described
the modification of a RAPTA complex with chlorambucil and
the variation of the co-ligands and the distance between the
Ru moiety and the alkylating agent chlorambucil. This strategy
led to compounds with in vitro anticancer activity in the low
µM range, being superior in cisplatin resistant cancer cells to
chlorambucil, RAPTA-T or a mixture of both. Mass spectrometry
studies showed that the η6-arene in 6 slowly cleaves in solution,
but is suﬃciently stable to result in a diﬀerent cytotoxic eﬀect
as compared to the combination of chlorambucil and RAPTA-T.
Moreover, the coordination of EtG to 6 following hydrolysis pro-
ceeds more rapidly than alkylation of EtG by the chlorambucil
fragment. Due to the instability of the ruthenium–arene bond,
alkylation of EtG is mainly observed for the free ligand and is
detected as an [LOH − Cl + EtG]+ ion, but this reaction also
takes place with 6, as peaks that may be assigned to [(LOH)Ru-
(PTA) + EtG − 2H]+ and [(LOH)Ru(PTA)(OH) + EtG − H]+ are
observed. Peaks assigned to cross-linked species indicate that
the design strategy for such a compound is feasible. However,
further refinement of the compound class is needed to increase
the stability of the Ru–arene bond to obtain a higher extent of
simultaneous protein ruthenation and DNA alkylation.
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